The thrombogenicity of the dienogest/estradiol valerate-containing oral contraceptive (Qlaira®)

Completed

• Conditions: blood clot; Venous thrombosis; 10064477

• Registration Number: NL-OMON35104
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Women, age 18-35 years, the wish to use dienogest/estradiol valerate or levonorgestrel/ethinylestradiol as oral contraceptive.

Exclusion Criteria

People who are legally incapable, contra-indications for the use of oral contraceptives as described by the WHO and Dutch Society of Gynaecologists, pregnancy during or in the three months before the trial, use of medication which can influence coagulation, chronic/acute illness.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Thrombin generation based-APC-resistance and SHBG.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Factor V Leiden and prothrombin mutation.</p><br>